Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Puma Biotechnology (PBYI) Shares Outstanding (Weighted Average) (2017 - 2025)

Puma Biotechnology's Shares Outstanding (Weighted Average) history spans 9 years, with the latest figure at $50.0 million for Q4 2025.

  • For Q4 2025, Shares Outstanding (Weighted Average) rose 2.8% year-over-year to $50.0 million; the TTM value through Dec 2025 reached $50.0 million, up 2.8%, while the annual FY2025 figure was $50.0 million, 2.8% up from the prior year.
  • Shares Outstanding (Weighted Average) reached $50.0 million in Q4 2025 per PBYI's latest filing, down from $50.3 million in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $50.3 million in Q3 2025 to a low of $40.3 million in Q1 2021.
  • Average Shares Outstanding (Weighted Average) over 5 years is $46.0 million, with a median of $46.9 million recorded in 2023.
  • Peak YoY movement for Shares Outstanding (Weighted Average): grew 2.47% in 2021, then increased 11.65% in 2022.
  • A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $40.6 million in 2021, then grew by 9.93% to $44.7 million in 2022, then increased by 5.51% to $47.1 million in 2023, then grew by 3.21% to $48.6 million in 2024, then rose by 2.8% to $50.0 million in 2025.
  • Per Business Quant, the three most recent readings for PBYI's Shares Outstanding (Weighted Average) are $50.0 million (Q4 2025), $50.3 million (Q3 2025), and $49.6 million (Q2 2025).